Fundraising Fox
Unravel Biosciences
Boston, US · Founded 2021 · 7 known investors
Find your way into Unravel Biosciences
Each arrow is one introduction. Sign up to fill in the first one.
Ask Tuoyo Louis to introduce you to Richard Novak
You →Tuoyo · together at Emory University →Richard
Ask Jamie Chen to introduce you to Frederic Vigneault
You →Jamie · together at University of Massachusetts Boston →Frederic
Sign up to find every way you can get introduced to Unravel Biosciences
- Your email: who you already know at Unravel Biosciences, and who your contacts know
- 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Unravel Biosciences team
- Your LinkedIn: the connections who can make the intro for you
We rank every route by how warm it is, so you raise on warm intros instead of cold emails.
Unravel Bio uses computational drug discovery and advanced animal models to accelerate pharmaceutical development with lower cost and risk. The company serves biopharma partners, foundations, and patients seeking treatments for rare and complex diseases.
Founders & leadership
Unravel Biosciences was founded in 2021 by Richard Novak and Frederic Vigneault.
Investors · 7
How we know: Bacchus Venture Capital's portfolio page · Not right? Tell us
How we know: Icebook Investments Corp.'s portfolio page · Not right? Tell us
How we know: Slingshot Ventures's portfolio page · funding news · Not right? Tell us
How we know: funding news · Not right? Tell us
How we know: the VCSheet dataset · Not right? Tell us
How we know: funding news · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$5.1M disclosed across 3 rounds · 2021–2026
▶$4.1MraisedAug 2026 · 2 investors · BiotechnologyRule 506(b)
- Richard NovakExecutive Officer, Director
- Frederic VigneaultDirector
- Donald IngberDirector
- Offering amount
- $4.5M
- Amount sold
- $4.1M
- First sale
- Aug 2026
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$500KraisedMar 2023 · 4 investors · BiotechnologyRule 506(b)
- Frederic VigneaultExecutive Officer, Director
- Donald IngberDirector
- Richard NovakExecutive Officer, Director
- Offering amount
- $2M
- Amount sold
- $500K
- First sale
- Feb 2023
- Incorporated
- Corporation, Delaware, 2021
- Federal exemptions
- 06b
▶$500KraisedAug 2021 · 3 investors · BiotechnologyRule 506(b)
- Richard NovakExecutive Officer, Director
- Donald IngberDirector
- Frederic VigneaultExecutive Officer, Director
- Lewis GeffenExecutive Officer
- Offering amount
- $1M
- Amount sold
- $500K
- First sale
- Jul 2021
- Incorporated
- Corporation, Delaware, 2021
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
In the news
Frequently asked questions
- What does Unravel Biosciences do?
- Unravel Bio uses computational drug discovery and advanced animal models to accelerate pharmaceutical development with lower cost and risk. The company serves biopharma partners, foundations, and patients seeking treatments for rare and complex diseases.
- Who founded Unravel Biosciences?
- Unravel Biosciences was founded by Richard Novak, Frederic Vigneault in 2021.
- Who are Unravel Biosciences's investors?
- Unravel Biosciences's investors include Bacchus Venture Capital, Beresford Ventures, Icebook Investments Corp., Slingshot Ventures, Active Partners, BoxOne Ventures, Nauta Capital.
- How much funding has Unravel Biosciences raised?
- Unravel Biosciences has disclosed $5.1M raised across 3 rounds.
- Where is Unravel Biosciences headquartered?
- Unravel Biosciences is headquartered in Boston, US.